TABLE 2.
PD model parameters
| Parametera | Estimated value (95% CI) |
|||
|---|---|---|---|---|
| Molnupiravir + camostat | Molnupiravir + brequinar | Molnupiravir + avoralstat | Molnupiravir + nafamostat | |
| a | 1.787 (0.7468–2.827) | 3.85 (2.923–4.778) | 3.314 (0.9883–5.639) | 1.061 (0.6793–1.443) |
| h EIDD | 1.139 (0.8407–1.437) | 1.001 (0.8819–1.12) | 1.181 (0.8145–1.548) | 1.026 (0.8033–1.249) |
| h 2 | 1.662 (1.257–2.066) | 0.7289 (0.6431–0.8146) | 1.748 (1.307–2.188) | 0.9372 (0.7622–1.112) |
| IC50 (μM) | ||||
| IC50,EIDD | 0.1383 (0.05129–0.2253) | 0.09877 (0.07293–0.1246) | 0.1883 (0.04864–0.328) | 0.2866 (0.1662–0.4071) |
| IC50,2 | 0.533 (0.3205–0.7456) | 2.858 (1.731–3.985) | 1.265 (0.7121–1.819) | 0.04567 (0.02515–0.0662) |
| R 2 | 0.9523 | 0.9851 | 0.945 | 0.959 |
a
h2 and IC50,2 represent the Hill coefficient and the IC50 of camostat, brequinar, avoralstat, and nafamostat, respectively, for each drug combination.